Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent's PD-1 Approved in China for First-Line NSCLC Indication

publication date: Feb 3, 2021

Suzhou Innovent Biologics and its partner Eli Lilly announced China approved its supplemental NDA of their partnered anti-PD-1 drug, Tyvyt® (sintilimab injection), as a first-line treatment for nonsquamous non-small cell lung cancer. Tyvyt will be administered in combination with pemetrexed and platinum chemotherapy. In 2018, Tyvyt was first approved in China as a third-line treatment for Hodgkin's lymphoma. Innovent is conducting over 20 Tyvyt clinical studies, including more than 10 registrational or pivotal clinical trials. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.